Clinical and neurobiological research suggests existence of discrete NM subtypes, particularly in untreated/early PD patients.

Description of six NMS dominant phenotypes of PD combining clinical, biomarker and pathophysiological concepts.

NMS subtyping would enrich the design of clinical trials and recruitment of patients.

NNMS subtyping would improve the knowledge about the natural history of PD so far only addressed for motor symptoms.